Lupin Limited LUPIN.NS · Stock Open Lupin Limited in new tab
Lupin Limited Analysis (LUPIN.NS)
Is Lupin Limited a good investment? Lupin Limited (LUPIN.NS) is currently trading at 2031.20 INR. Market analysts have a consensus price target of 2477.11 INR. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 17.33. This valuation is generally in line with the broader market.
Earnings Schedule: Lupin Limited is expected to release its next earnings report on Nov. 11, 2026. The market consensus estimate for Forward EPS is 102.17.
For income investors, Lupin Limited pays a dividend yield of 0.86%. With a payout ratio of 10%, the dividend appears sustainable.
Investor FAQ
Does Lupin Limited pay a dividend?
Yes, it pays an annual dividend of 18.00 INR (0.86% yield).
What asset class is Lupin Limited?
Lupin Limited is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 11, 2026. The company currently has a trailing EPS of 120.71.
Company Profile
Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India, the United States, and internationally. The company operates in two segments: Pharmaceuticals and Others. It produces, develops, and markets various branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs). The company also offers products in the therapeutic areas of cardiovascular, diabetology, asthama, pediatrics, central nervous system, gastro-intestinal, anti-infectives, anti-TB, cephalosporins, and nonsteroidal anti-inflammatory drug therapies. In addition, it provides chronic therapies, and hospital-based products; products for diabetes and iron supplements for anemia, and a Budesonide-Formoterol combination for asthma. Further, the company is involved in the provision of diagnostics services, and digital healthcare services; and neuro rehabilition business. It operates through network consisting of labs and collection centers. The company has a strategic collaboration with TB Alliance to support the clinical development and commercialization of Telacebec for the treatment of tuberculosis, leprosy, and buruli ulcer. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.
| Year | Total Dividends |
|---|---|
| ▸2027 |
27.00 INR
|
| Sept. 1, 2027 (estimated) | 27.0000 |
| ▸2026 |
18.00 INR
|
| Sept. 3, 2026 | 18.0000 |
| ▸2025 |
12.00 INR
|
| Sept. 10, 2025 | 12.0000 |
| ▸2024 |
8.00 INR
|
| Sept. 1, 2024 | 8.0000 |
| ▸2023 |
4.00 INR
|
| Sept. 2, 2023 | 4.0000 |
| ▸2022 |
4.00 INR
|
| Sept. 2, 2022 | 4.0000 |
| ▸2021 |
6.50 INR
|
| Aug. 17, 2021 | 6.5000 |
| ▸2020 |
6.00 INR
|
| Aug. 19, 2020 | 6.0000 |
| ▸2019 |
5.00 INR
|
| Sept. 6, 2019 | 5.0000 |
| ▸2018 |
5.00 INR
|
| Sept. 7, 2018 | 5.0000 |
| ▸2017 |
7.50 INR
|
| Sept. 1, 2017 | 7.5000 |
| ▸2016 |
7.50 INR
|
| Sept. 2, 2016 | 7.5000 |
| ▸2015 |
7.50 INR
|
| Aug. 22, 2015 | 7.5000 |
| ▸2014 |
6.00 INR
|
| July 29, 2014 | 3.0000 |
| March 5, 2014 | 3.0000 |
| ▸2013 |
4.00 INR
|
| Sept. 6, 2013 | 4.0000 |
| ▸2012 |
3.20 INR
|
| Aug. 23, 2012 | 3.2000 |
| ▸2011 |
3.00 INR
|
| Aug. 26, 2011 | 3.0000 |
| ▸2010 |
13.50 INR
|
| Aug. 27, 2010 | 13.5000 |
| ▸2009 |
12.50 INR
|
| Sept. 1, 2009 | 12.5000 |
| ▸2008 |
10.00 INR
|
| Sept. 1, 2008 | 10.0000 |
| ▸2007 |
5.00 INR
|
| Aug. 1, 2007 | 5.0000 |
| ▸2006 |
6.50 INR
|
| July 26, 2006 | 6.5000 |
| ▸2005 |
6.50 INR
|
| Aug. 3, 2005 | 6.5000 |
| ▸2004 |
6.50 INR
|
| July 30, 2004 | 6.5000 |
| ▸2003 |
5.00 INR
|
| Aug. 1, 2003 | 5.0000 |
| ▸2002 |
5.00 INR
|
| Sept. 4, 2002 | 2.5000 |
| Feb. 22, 2002 | 2.5000 |
| Name | Payment Date | Status | Amount |
|---|---|---|---|
| Lupin Limited | Sep 03, 2026 | Paid | 18.0 INR |
| Split Date | Split Ratio to 1 |
|---|---|
| Aug. 11, 2006 | 2:1 |
| Aug. 27, 2010 | 5:1 |
Community Discussion